Bayer Pharmaceuticals, a division of Johnson & Johnson, is facing about 6,400 federal lawsuits filed by patients who suffered complications from the bloodthinner Xarelto (rivaroxoaban). The first four of these lawsuits is scheduled to go to trial in early 2017 in U.S. District Court for the Eastern District of Louisiana.
The lawsuits filed against Bayer allege that patients who used Xarelto face an increased risk of severe bleeding events compared with other bloodthinning medications. Xarelto was released by Bayer in 2011 to treat patients at risk of deep vein thrombosis (blood clots in the arms or legs) or pulmonary embolism (blood clots in the lungs), and to reduce the risk of strokes in patients with an irregular heart rhythm.
Xarelto was marketed as an alternative to another bloodthinner, Coumadin (warfarin), which had been in use for roughly 60 years. Because patients taking Xarelto do not need to have monthly blood tests (unlike patients taking warfarin), the drug was marketed as easier for patients to use. However, unlike warfarin, Xarelto has no antidote that would allow doctors to reverse the bloodthinning effects of the drug. As a result, patients who suffered bleeding events while being treated with Xarelto faced an increased risk of severe and potentially fatal bleeding.
Lawsuits filed against Bayer allege that the drugmaker did not properly warn doctors and patients about the increased risk of severe bleeding events that could be caused by Xarelto. It was only after Xarelto went on the market that the FDA required Bayer to update the drug’s warning label to include information about the risk of severe bleeding events associated with the medication.
The Xarelto lawsuits that will go to trial early next year are bellwether trials, cases which are chosen from a large pool of litigants in order to expedite the litigation process and pave the way for a potential settlement. The first Xarelto bellwether trial will be selected from plaintiffs who originally filed a lawsuit against Bayer in Louisiana and were 50-90 years old at the time they suffered a severe bleeding event. The second bellwether trial will involve a patient who suffered a stroke that resulted in serious injury or death. The third trial will involve plaintiffs who suffered gastrointestinal bleeding, were 40-80 years old when the event occurred, and who originally filed their lawsuit in Mississippi. The fourth bellwether trial will involve a case filed in Texas.
Xarelto Lawsuits Filed by Heygood, Orr & Pearson
If you or a loved one have suffered gastrointestinal bleeding or other severe bleeding events caused by Xarelto, you may qualify to file a lawsuit. The first step in taking legal action is to speak with an experienced pharmaceutical litigation attorney who can guide you through the process of filing a claim.
The lawyers at Heygood, Orr & Pearson have filed hundreds of lawsuits on behalf of patients who were injured by complications from dangerous drugs. Our law firm has already filed several claims on behalf of patients who suffered complications from Xarelto or Pradaxa, another bloodthinner linked to severe bleeding events. Our attorneys have also filed numerous lawsuits on behalf of patients who were injured after taking other dangerous medical devices or pharmaceutical products, including fentanyl, Yasmin, Actos, Avandia, and Zofran.
The attorneys at Heygood, Orr & Pearson have based our careers on the notion that companies who manufacture and sell dangerous drugs or medical devices should be held responsible in court for the injuries caused by these products. Heygood, Orr & Pearson has tried hundreds of cases to verdict and has achieved settlements in hundreds more on behalf of our clients. Our attorneys have achieved verdicts and settlements on our clients’ behalf totaling more than $200 million.
For more information about the Xarelto litigation and to receive a free consultation to learn whether you may qualify to file a case, contact the lawyers at Heygood, Orr & Pearson by calling toll-free at 1-877-446-9001. You can also reach us by following this link to our free case evaluation form and answering a few brief questions to get started.